Zusammenfassung
About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising single agent activity in multiple relapsed HL, we replaced bleomycin in ABVD with lenalidomide in this phase-I trial. Patients aged >= 60 years with early-unfavourable- or advanced-stage HL (Eastern Cooperative Oncology Group performance status <= 2, Cumulative Illness Rating Scale for Geriatrics ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric